Telix Pharmaceuticals (ASX:TLX) completed the acquisition of US-based biotechnology company ImaginAb for an upfront consideration of $45 million, according to a Friday filing with the Australian bourse.

The company paid $10 million in cash and $31 million in equity through the issue of about 2.1 million shares, with a deferred payment of up to $4 million in equity at the end of a 15-month indemnity period, the filing said.

The company will pay up to $185 million upon achieving key development and commercial milestones, per the filing.

Shares rose 1% in morning trade Friday and earlier reached an all-time high.